A phenocopy of CAII deficiency: a novel genetic explanation for inherited infantile osteopetrosis with distal renal tubular acidosis


The rare bone thickening disease osteopetrosis occurs in various forms, one of which is accompanied by renal tubular acidosis (RTA), and is known as Guibaud-Vainsel syndrome or marble brain disease. Clinical manifestations of this autosomal recessive syndrome comprise increased bone density, growth failure, intracerebral calcification, facial dysmorphism, mental retardation, and conductive hearing impairment. The most common cause is carbonic anhydrase II (CAII) deficiency. Several different loss of function mutations in CA2, the gene encoding CAII, have been described. To date, there have been no exceptions to the finding of CAII deficiency in patients with coexistent osteopetrosis and RTA. Most often, the RTA is of mixed proximal and distal type, and kindreds are reported in which either proximal or distal RTA predominates.

We report the molecular genetic investigation of two consanguineous kindreds where osteopetrosis and distal RTA (dRTA) were both manifest. One kindred harbours a novel homozygous frameshift alteration in CA2. In the other, CAII levels were normal despite a similar clinical picture, and we excluded defects in CA2. In this kindred, two separate recessive disorders are penetrant, each affecting a different, tissue specific subunit of the vacuolar proton pump (H\(^+\)-ATPase), providing a highly unusual, novel genetic explanation for the coexistence of osteopetrosis and dRTA. The osteopetrosis is the result of a homozygous deletion in TICRG1, which encodes an osteoclast specific isoform of subunit a of the H\(^+\)-ATPase, while the dRTA is associated with a homozygous mutation in ATP6V1B1, encoding the kidney specific B1 subunit of H\(^+\)-ATPase. This kindred is exceptional firstly because the coincidental occurrence of two rare recessive disorders has created a phenocopy of CAII deficiency, and secondly because these disorders affect two different subunits of the H\(^+\)-ATPase that have opposite effects on bone density, but which have only recently been determined to possess tissue specific isoforms.

The association of osteopetrosis and renal tubular acidosis (RTA) was first described in 1972, and it is also referred to as Guibaud-Vainsel syndrome or marble brain disease (MIM 259730, http://www.ncbi.nlm.nih.gov/Omim/).\(^1\) Clinical manifestations of this autosomal recessive syndrome comprise increased bone density, intracerebral calcification, mental retardation, growth failure, and facial dysmorphism. In 1983, Sly et al.\(^2\) showed that in patients with this syndrome, carbonic anhydrase II (CAII) activity in erythrocytes was absent, suggesting that this was the primary defect. Several different loss of function mutations in CA2, the gene encoding this protein, have since been described. To date there have been no exceptions to the finding of CAII deficiency in patients with coexistent osteopetrosis and RTA. Most often, the RTA is of mixed proximal and distal type, consistent with the known expression pattern of CA2 in both proximal convoluted tubule and collecting duct.\(^3\) However, kindreds are reported in which either proximal or distal RTA predominates.\(^3\) We report here two families where osteopetrosis and distal RTA (dRTA) were both manifest, but in one we could exclude defects in CA2 as the cause and therefore sought an alternative genetic explanation.

METHODS
Participating families
Kindred 1
The index male, case A, was the first offspring of a central Turkish first cousin union (pedigree structure shown in fig 1). He was delivered spontaneously following a 40 week uncomplicated pregnancy, weighing 3080 g. At 10 days old and weighing 2960 g, he developed pneumonia, difficulty in feeding, and convulsions. Facial dysmorphism was prominent, with low set ears, hypertelorism, and a depressed nasal bridge.

Laboratory data on admission were as listed in table 1, showing hyperchloremic metabolic acidosis. Urinary pH was 7 and remained higher than 5.5 during all episodes of spontaneous metabolic acidosis. There was transient trace proteinuria that resolved spontaneously; urine amino acids were normal. Following rehydration, renal function was otherwise normal. Alkaline phosphatase was raised and x rays showed increased bone density, with a “bone within bone” appearance in the tubular bones (fig 2) characteristic of osteopetrosis.

Therapy was started with Shohl solution (citric acid and sodium citrate), vitamin D3, and temporary supplementation of calcium. He was readmitted at 2 months of age with fever, respiratory distress, and difficulty feeding. His weight had fallen further to 2750 g and length was 51 cm (<3rd centile). Physical examination disclosed pneumonia, pallor, and hepatosplenomegaly. He could fix his eyes to light and on his mother, and pupillary reactions were normal. He responded normally to sound, but compliance for auditory evoked responses could not be obtained. Laboratory data were as in table 1, showing persistence of the metabolic acidosis. Severe hypokalaemia subsequently developed, and distal renal tubular acidosis was diagnosed. The urinary Ca:Cr ratio was raised at 0.15-0.45 on several occasions during this admission. He had become markedly anaemic (Hb 7.2 g/dl). The total white cell count had risen to 32 × 10\(^6\)/l, and a peripheral blood smear showed a marked left shift. Renal ultrasonography showed increased medullary echogenicity suggestive of nephrocalcinosis. Intracranial calcification was not observed on conventional radiography. The dose

www.jmedgenet.com
of Shohl solution was increased to 4-5 ml/kg and additional potassium supplementation was administered. However, he remained unwell with severe growth retardation and died at 12 months of age.

Case B, the sister of case A, presented at 3.5 months because of poor feeding and poor weight gain. She too was the product of a normal, term pregnancy and delivery. She was also growth retarded (length 57 cm, 10th centile; weight 3500 g, <5th centile for age). Laboratory investigations (table 1) again showed hypokalaemic metabolic acidosis with inappropriately alkaline urine, consistent with dRTA. Mild hypercalciuria was present, and medullary nephrocalcinosis was found on renal

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Case A, first admission</th>
<th>Case A, second admission</th>
<th>Case B</th>
<th>Case C</th>
<th>Case D</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma sodium (mEq/l)</td>
<td>138</td>
<td>141</td>
<td>135</td>
<td>139</td>
<td>138</td>
</tr>
<tr>
<td>Plasma potassium (mEq/l)</td>
<td>5.6</td>
<td>4.2 → 1.5</td>
<td>2.8</td>
<td>4.2</td>
<td>4.3</td>
</tr>
<tr>
<td>Plasma chloride (mEq/l)</td>
<td>120&lt;sup&gt;a&lt;/sup&gt;</td>
<td>118&lt;sup&gt;a&lt;/sup&gt;</td>
<td>111&lt;sup&gt;a&lt;/sup&gt;</td>
<td>123&lt;sup&gt;a&lt;/sup&gt;</td>
<td>109&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Plasma bicarbonate (mEq/l)</td>
<td>10.9&lt;sup&gt;a&lt;/sup&gt;</td>
<td>13.1&lt;sup&gt;a&lt;/sup&gt;</td>
<td>13.4&lt;sup&gt;a&lt;/sup&gt;</td>
<td>10.7&lt;sup&gt;a&lt;/sup&gt;</td>
<td>13.5&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Plasma creatinine (mg/dl)</td>
<td>0.7&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma calcium (mg/dl)</td>
<td>5.5&lt;sup&gt;a&lt;/sup&gt;</td>
<td>9.2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma phosphate (mg/dl)</td>
<td>5.2</td>
<td>3.9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma alkaline phosphatase (U/l)</td>
<td>1802&lt;sup&gt;a&lt;/sup&gt;</td>
<td>328</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood urea nitrogen (mg/dl)</td>
<td>23&lt;sup&gt;a&lt;/sup&gt;</td>
<td>21&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arterial pH</td>
<td>7.18&lt;sup&gt;a&lt;/sup&gt;</td>
<td>7.05&lt;sup&gt;a&lt;/sup&gt;</td>
<td>7.28&lt;sup&gt;a&lt;/sup&gt;</td>
<td>7.28&lt;sup&gt;a&lt;/sup&gt;</td>
<td>7.35&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Urine pH</td>
<td>7.0&lt;sup&gt;a&lt;/sup&gt;</td>
<td>7.0&lt;sup&gt;a&lt;/sup&gt;</td>
<td>7.0&lt;sup&gt;a&lt;/sup&gt;</td>
<td>8.0&lt;sup&gt;a&lt;/sup&gt;</td>
<td>7.0&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Urine calcium</td>
<td>0.43&lt;sup&gt;a&lt;/sup&gt; mg/mg creatinine</td>
<td>0.18&lt;sup&gt;a&lt;/sup&gt; mg/mg creatinine</td>
<td>12.2&lt;sup&gt;a&lt;/sup&gt; mg/kg/day</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hb (g/dl)</td>
<td>16.2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>7.2&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White cells (10&lt;sup&gt;9&lt;/sup&gt;/l)</td>
<td>12.5&lt;sup&gt;a&lt;/sup&gt;</td>
<td>32&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> = above the normal range for age; <sup>i</sup> = below the normal range for age.
ultrasound. Neither amino aciduria nor glycosuria was detected. Unlike her brother, she showed no sign of osteopetrosis on skeletal x ray at initial or subsequent assessment.

Oral potassium and bicarbonate supplementation in the form of Shohl solution and potassium citrate were started. She had less severe growth failure than her brother, but still weighed only 6 kg with length 70 cm at 12 months old. Audiography performed at the age of 3 years showed bilateral sensorineural hearing loss, which first became clinically evident three months earlier.

Kindred 2
This kindred was from northern Turkey and the two affected children were the product of a double first cousin union (fig 1). The female index case (case C) presented at the age of 8 years for evaluation of blindness, which had first been noted when she was 2 years old, and which was accompanied by severe growth impairment (<3rd centile for age); global mental retardation, conductive hearing loss, and calcification of the basal ganglia. Initial biochemical investigations, shown in table 1, were consistent with distal renal tubular acidosis, as in kindred 1. In addition, the urine anion gap was positive at baseline. The diagnosis of osteopetrosis with distal RTA was made in each kindred on the basis of clinical presentation, biochemical and haematological abnormalities, and radiographic features in the index cases. In kindred 2, the genetic cause of the syndrome was typical: a destructive mutation in ATP6V1B1 (see results) was typed in both parents and in 40 unrelated unaffected subjects by RFLP analysis using BstBI, identifying CA2 on chromosome 2 and TCIRG1 on chromosome 11, respectively were typed by PCR amplification of genomic DNA extracted from peripheral blood.

RESULTS
The diagnosis of osteopetrosis with distal RTA was made in each kindred on the basis of clinical presentation, biochemical and haematological abnormalities, and radiographic features in the index cases. In kindred 2, the genetic cause of the syndrome was typical: a destructive mutation in ATP6V1B1, as predicted by CAII activity which showed very low levels in both children and intermediate activity in both carrier parents (table 2), and by linkage analysis that showed homozygous identity by descent (fig 1A) at the CA2 locus. Both children were homozygous for the deletion of a single cytosine in CA2, lost from codon 207 (fig 1B). The resulting novel 15 amino acids culminate in a premature termination codon. While it was clear in kindred 1 that the index case had radiographic evidence of osteopetrosis, it was not apparent whether his sister (case B) had isolated dRTA or was simply failing to manifest radiographic changes of osteopetrosis because of the severity of her systemic acidosis, which is said to ameliorate the increase in bone density.

In contrast to kindred 2, activity of CAII was not reduced in kindred 1. The misense alteration G78R in ATP6V1B1 (see results) was typed in both parents and in 40 unrelated unaffected subjects by RFLP analysis using BstBI, identifying CA2 on chromosome 2 and TCIRG1 on chromosome 11, respectively were typed by PCR amplification of genomic DNA extracted from peripheral blood.

Measurement of carbonic anhydrase II
CAII activity for enzymatic diagnosis was assessed by the endpoint titration assay as previously described; CA1 activities were calculated by subtraction from the totals.

Genomic sequencing
All coding exons and flanking intronic regions of CA2, ATP6V1B1, and TCIRG1 were amplified and sequenced on an ABI-377 machine using the ABI Prism BigDye™ kit, according to the manufacturer’s protocol (PE Applied Biosystems, Foster City, CA, USA). Identified mutations were confirmed by repeat PCR amplification and sequencing on the opposite strand. The misense alteration G78R in ATP6V1B1 (see results) was typed in both parents and in 40 unrelated unaffected subjects by RFLP analysis using BstBI (New England Biolabs, Hitchin, UK). Exon 7 of TCIRG1 was separately amplified by PCR in all members of kindred 1 and products resolved by agarose gel electrophoresis.

Linkage analysis
Ethical approval for genetic studies was granted by the Cambridge Local Ethical Research Committee (99/078). Polymorphic loci flanking CA2, ATP6V1B1 (previously known as ATP6B1), and TCIRG1 on chromosomes 8, 2, and 11 respectively were typed by PCR amplification of genomic DNA extracted from peripheral blood. Incorporation of [α-32P]dCTP (Amersham Pharmacia Biotech, Little Chalfont, Buckinghamshire, UK) into the reaction mix was followed by electrophoresis under denaturing conditions and autoradiography, as previously described. SNPs located within ATP6V1B1 that had been identified during previous mutation analysis were typed by restriction digest and agarose gel electrophoresis following PCR amplification using primers in flanking sequences.
1A, linkage to CA2 could theoretically be excluded whether one or both children had osteopetrosis. The close consanguinity of the parents predicts homozygosity in an affected child across this segment of chromosome 8 by descent from one carrier great grandparent. The index case was heterozygous at this locus and, in addition, the two sibs were not haploidentical. Moreover, direct sequencing of all coding exons and exon-intron boundaries of CA2 in both children did not show any sequence alterations.

In view of the presence of sensorineural rather than conductive hearing loss in conjunction with dRTA in the surviving sib, we examined linkage to ATP6V1B1. This gene, which encodes the kidney specific B1 subunit of the apical H\(^+\)-ATPase (proton pump) responsible for urine acidification in the collecting duct, has been previously found to cause the syndrome of dRTA with deafness (MIM 267300).\(^{11}\) Linkage could not be excluded, as both children were homozygous by descent (fig 3A). We found that both children were homozygous for a missense mutation altering glycine at position 78 to arginine (fig 3B). This change resulted in loss of a BrsBI restriction site that was subsequently used to show that both parents were heterozygous (fig 3C), and that the alteration was absent from 80 control chromosomes.

We next assessed candidacy of TCIRG1 as the causative gene to account for the osteopetrosis in case A. This gene has recently been identified as the cause of isolated recessive malignant osteopetrosis.\(^{14,15}\) It encodes the osteoclast specific a3 isoform of the large accessory subunit in the H\(^+\)-ATPase responsible for acidification at the osteoclast-bone interface. Linkage analysis showed that he was homozygous across this segment while his sister was not (fig 4A), and he was discovered to have a novel, homozygous 26 bp deletion starting in codon 216 (fig 4B), resulting in an almost immediate termination codon that would severely truncate the protein. His sister and both parents were heterozygotes, as shown by PCR amplification of this region of the gene (fig 4C).

**DISCUSSION**

The hereditary skeletal disorder osteopetrosis is primarily characterised by increased bone radiodensity. The neurological manifestations of blindness and deafness in osteopetrosis are usually attributed to nerve compression by the abnormal and

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Carbonic anhydrase isoenzyme I and II activity in red blood cells</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total CA (U/mg Hb)</td>
</tr>
<tr>
<td>Case A</td>
<td>30.0</td>
</tr>
<tr>
<td>Case B</td>
<td>12.5</td>
</tr>
<tr>
<td>Father</td>
<td>17.3</td>
</tr>
<tr>
<td>Mother</td>
<td>15.6</td>
</tr>
<tr>
<td>Case C</td>
<td>7.7</td>
</tr>
<tr>
<td>Case D</td>
<td>9.7</td>
</tr>
<tr>
<td>Father</td>
<td>11.8</td>
</tr>
<tr>
<td>Mother</td>
<td>11.7</td>
</tr>
</tbody>
</table>
| Normal ranges (mean (SEM)): total CA 16.4 (3.0) U/mg Hb, CAII 8.1 (2.0) U/mg Hb, CAI levels calculated following addition of NaI.\(^{12,13}\)
deformed bone. It occurs in several forms; those arising as recessive traits are usually much more severe than the autosomal dominant type. In addition, the “infantile malignant” form caused by mutation in \( \text{TCIRG1} \) is generally even more severe than the commoner variety resulting from \( \text{CAII} \) deficiency. In contrast, bone mineral density is decreased by the acidosis of distal RTA, with overt rickets appearing in untreated cases, and the associated hearing impairment is sensorineural rather than conductive.

Until now, the association of osteopetrosis with RTA has always implied that \( \text{CA2} \) is the responsible gene. The novel destructive \( \text{CA2} \) mutation we found in the second kindred adds to the 16 different mutations previously reported in families with \( \text{CAII} \) deficiency syndrome. The commonest of these, colloquially known as the Arabic mutation, leads to loss of the donor splice junction of intron 2. It accounts for almost all cases in North Africa and the Arabian peninsula, which comprise 75% of all those reported. An interesting study found that affected families were all descended from the same nomadic tribe (Helal) in the 10th century. Despite the appearance of this tribe as far north as Greece, \( \text{CAII} \) deficiency has never been reported in Turkey until this year. In addition to the second kindred described here, with its novel \( \text{CA2} \) mutation, a recent report identified another Turkish kindred with this syndrome; however, apart from excluding the Arabic mutation, no further genetic information was presented.

At first glance, kindred 1 might have fit the diagnostic mould of \( \text{CAII} \) deficiency, with case B escaping radiological detection of bone thickening because of demineralisation secondary to the systemic acidosis, as has previously been suggested. Strikingly, however, carbonic anhydrase II levels were not diminished in any member of this family, and our genetic studies showed that \( \text{CA2} \) could not be the responsible gene.

Kindred 1 is particularly unusual because we have found two separate genetic traits that affect bone density in opposite ways, since dRTA is associated with osteopenia. Recessive osteopetrosis was diagnosed in the first child of this family because of the typical symptoms in early infancy. Although detailed studies of auditory and optic nerves could not be performed, retinal examination showed peripapillary chorioretinal atrophy, which is also compatible with osteopetrosis. Despite appropriate attempts to correct the metabolic effects, case A failed to thrive and when he died still weighed only 3500 g, with length 53 cm. The severity of the metabolic derangement, very young age at presentation, and resistance to appropriate therapy would have been unusual for \( \text{CAII} \) deficiency, but is more in keeping with the infantile malignant form. The presence of the homozygous destructive mutation in \( \text{TCIRG1} \), causing loss of the a3 subunit from osteoclast proton pumps, combined with primary recessive dRTA, suggests that his poor clinical progress despite treatment was probably inevitable. Bone marrow transplantation might have been considered had he survived, but while this is reported to rescue the bone disease of \( \text{CAII} \) deficiency, it cannot ameliorate the RTA.

The second child's hearing impairment, in the absence of osteopetrosis, but in the context of distal renal tubular acidosis, led to the assessment of \( \text{ATP6V1B1} \) as a causative gene. It became evident that both cases A and B have this recessive form of dRTA. The mutation we identified is novel and is unlikely to represent a neutral polymorphism. Firstly, it was absent in controls, secondly it replaces a neutral hydrophobic residue with a positively charged hydrophilic one, and thirdly it lies in a domain of the encoded protein whose \( \beta \) barrel conformation is particularly well conserved across species. Furthermore, other disease causing mutations have been identified in this same domain.

---

**Figure 4** Genetic analysis of \( \text{TCIRG1} \) in kindred 1. (A) Only the index case is likely to harbour mutations in this gene. Markers and distances on chromosome 11 are displayed as in fig 1. (B) Direct sequencing in the index case showed a homozygous 26 bp deletion starting at W216 in exon 7. (C) This mutation permits resolution by product size difference following PCR amplification of this exon. Both unaffected parents and sib were heterozygous carriers. WT = 138 bp; mut = 112 bp.
These two inherited disorders affect two different subunits of the vacuolar proton pump that have only in recent years been determined to possess tissue specific isoforms. The B and α subunits are known to be encoded by two and four different genes respectively, and this knowledge has in part been derived from the investigation of rare Mendelian kindreds. B1 is one of the subunit isoforms that makes the H⁺-ATPase on the luminal membrane of the kidney α intercalated cell unique, and α3 is the only known osteoclast specific subunit of the H⁺-ATPase (fig 5). Although their overall multi-subunit composition is probably the same, the ubiquitously expressed intracellular proton pumps that are responsible for organelle acidification contain the B2 and α1 subunits. Proper function of proton pumps containing the tissue specific gene products, present at high density at the cell surface, is essential for homeostasis in both kidney and bone. The B subunit, forming part of the V₁ catalytic domain responsible for ATP hydrolysis, is known to be necessary for this hydrolysis to proceed. In contrast, the contribution of the α subunit to overall pump function has yet to be elucidated in mammals. Evidence from yeast studies suggests its involvement in transmembrane proton translocation and/or stabilisation of the pump complex.

TCIRG1 contains two transcription initiation sites, upstream of exon 1 and within exon 5 respectively. The shorter transcript, TCIRG7, is reported to be expressed only in the immune system. The 26 bp deletion observed in case A removes TCIRG7’s initial methionine codon, in addition to severely truncating α3. This begs the question of whether the haematological abnormalities observed in case A are attributable to previously recognised osteopetrosic marrow failure, or whether loss of TCIRG7 predicted by the mutation might be relevant. However, to date, the potential functions of the TCIRG7 protein have not been characterised.

This kindred is also noteworthy in that the two rare recessive genetic disorders present in the index case together create a phenocopy of a third. This sibship illustrates the importance of clinical characterisation of all affected members of such a kindred. It is difficult in this population, where consanguinity is prevalent, to estimate the allele frequency for either recessive osteopetrosis or dRTA. Using a figure of 1:200 for either, the odds of case A inheriting both traits would be tens of millions to 1.

ACKNOWLEDGEMENTS

The second and third authors contributed equally to this work. This work was supported by the Wellcome Trust, of which KJB is a Prize student and FEK is a Senior Clinical Research Fellow. We thank the families for their participation, and Annabel Smith for invaluable assistance.

Authors’ affiliations

K J Borthwick, F E Karet, Department of Medical Genetics, Cambridge University, Cambridge, UK
N Kandemir, R Topaloglu, A Bakaloglu, N Yordam, S Ozen, Faculty of Medicine, Hacettepe University, Ankara, Turkey
N Kandemir, A Bakaloglu, N Yordam, Division of Paediatric Endocrinology and Rheumatology, Hacettepe University, Ankara, Turkey
R Topaloglu, S Ozen, Division of Paediatric Nephrology, Hacettepe University, Ankara, Turkey
U Kornak, Zentrum für Molekulare Neurobiologie Hamburg, Hamburg University, Hamburg, Germany
H Mocan, Department of Paediatrics, Metropolitan Florence Nightingale Hospital, Istanbul, Turkey
REFERENCES


